Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.

Trial Profile

Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary)
  • Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Lymphoma; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Feb 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 22 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov.
    • 06 Feb 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top